Issues of fertility, body image and sexuality are all important when treating a young adult with cancer, yet many facilities lack proper utilities and training to assist this group of patients, which is why Anne Katz wrote the book, "This Should Not Be Happening: Young Adults with Cancer."
On the evolving role of PARP inhibitors in the treatment of ovarian cancer, Donna McNamara, co-chief of Gynecological Oncology at the John Theurer Cancer Center (JTCC), discusses the impact of these studies and the outlook going forward.
There's a list of things we're supposed to do as good patients. And then, there's the reality of living with cancer and doing the best we can.
Women diagnosed with early-stage breast cancer have a variety of decisions to make regarding treatment, but it's important for patients to realize all of their options when making those medical decisions.
In which Kevin introduces himself, catches the world up to date on his cancer battle, and sprinkles in some random bits of wisdom
A phase 3 study of Gazyva in indolent non-Hodgkin lymphoma has been stopped early after an interim analysis found the drug improved progression-free survival.
Each year on Feb. 4, people from around the world recognize World Cancer Day, an initiative to increase awareness of the global burden of cancer and promote strategies for reducing cancer incidence and death rates.
The anticipated approval of Ibrance (palbociclib) came two months ahead of expectations, as the FDA granted an accelerated approval to the drug as a frontline treatment for women with ER-positive, HER2-negative metastatic breast cancer.
Carl Harrington, president of the International Waldenstrom's Macroglobulinemia Foundation (IWMF), explains the importance of Imbruvica's approval for the rare disease.
The Food and Drug Administration (FDA) granted a priority review to Yondelis to treat patients with the disease, including liposarcoma and leiomyosarcoma subtypes, who have previously received chemotherapy that included an anthracycline. The FDA will make its final approval decision within six months.
Knowing how genes and nutrients interact could likewise be the prescription for improved health.
Cancer moves fast; we need to move faster. Help make sure patients have access to important diagnostic tests.
The PD-L1 inhibitor MPDL3280A has received a breakthrough therapy designation from the FDA for PD-L1–positive non–small cell lung cancer (NSCLC) that has progressed on prior therapy.
The FDA's framework for regulating lab developed tests could keep some patients from receiving validated diagnostic tests and targeted treatments like mine.
During President Barack Obama's State of the Union Address, he announced a nationwide Precision Medicine Initiative that would help cure diseases such as cancer and diabetes.
Melanoma specialist, Suzanne L. Topalian discusses how new approved drugs and those in the pipeline for advanced melanoma are making an impact for patient.
A new study has found that while the breast cancer prevention drug tamoxifen's benefits outweigh its risks, the drug isn't right for all women.
Ibrutinib becomes the first drug specifically approved for Waldenstrom's macroglobulinemia (WM), two months ahead of expectations.
Every day, breast cancer researcher Edith Perez sets her mind on finding better treatments for the disease and conducting research aimed at improving patients' lives.
When motivating people to get screened for cancer, fear may not be the best way to do it.
The Food and Drug Administration is evaluating proposals for new indications for at least 17 oncology medicines, according to Friends of Cancer Research, an advocacy group that aims to get patients cutting-edge treatments as safely and quickly as possible.
An analysis of patients with advanced hepatocellular carcinoma and elevated AFP who received second-line Cyramza showed improved survival, according to data from the phase 3 REACH study.
There is a lot of pressure on cancer patients to stay cheerful and only focus on the positive during treatment and beyond. I think this is overrated and can stifle the process of coming to terms with this disease.
Recent results from the phase 2 TERRAIN trial showed Xtandi increased progression-free survival by nearly 10 months compared with Casodex in patients with metastatic castration-resistant prostate cancer.
The integrative treatment of cancer must include nutrition as an adjunct to surgery, radiation therapy and chemotherapy.
Immune checkpoint inhibitors targeted against PD-1 and its ligand PD-L1 have rapidly advanced as treatments for patients with melanoma and non-small cell lung cancer (NSCLC), following their initial debut in 2012. What's next?
The emotional fallout of cancer takes a heavy toll. Experiencing your feelings in your own way, at your own pace, can be a challenge.
The Food and Drug Administration granted a Fast Track Designation to CPX-351 for the treatment of elderly patients with relapsed acute myeloid leukemia (AML).
Most oncologists are well acquainted with the term precision medicine, often used interchangeably to describe a model of care in which a treatment plan is based on patient characteristics and the molecular and genetic profile of the patient's tumor.
Two recent studies outline the importance of nutrition in preventing obesity-related cancers, as well as the potential benefits of a nutrition education intervention in preventing breast cancer recurrence.
